Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas

This study has been completed.
Sponsor:
Collaborator:
Celgene
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT01730586
First received: October 26, 2012
Last updated: August 12, 2016
Last verified: August 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: August 2016
  Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)